4 questions lodged at 2026 Australian Clinical Labs (ACL) hybrid AGM
October 28, 2026
Below is the text of the 4 written questions submitted at the Australian Clinical Labs (ACL) 2pm AEDT virtual AGM via the MUFG platform on August 28, 2026. See notice of meeting detailing 6 voting resolutions. Market cap $556m on AGM day. The proxies were disclosed early in the formal addresses. There were no protest votes.
Q1. Which of the proxy advisers covered us this year and did any recommend a vote against any of today's resolutions, including this remuneration report item? If so, what reasons did they give and did this translate into any material protest votes? Please don't say they are confidential. It is standard for companies to be across this detail on the voting recommendations and inform shareholders where relevant.
Answer: Was jammed at Dexus so waiting for the archive to see how they responded.
Q2. What are the material differences between the incentive arrangements for the new CEO and those which applied to his predecessor. Also, retail voting sentiment on rem issues is often different from the 10 largest shareholders who control public company voting outcomes. Will you disclose the headcount data on all resolutions to the ASX to make public retail voting sentiment and the chronically low retail participation rate? Did even 2% of shareholders vote by proxy ahead of this meeting?
Answer: Was jammed at Dexus so waiting for the archive to see how they responded.
Q3. How many full time equivalent staff do we currently have and is this likely to fall over the coming 12 months with the rapid roll out of AI? Which parts of our business and operations are the most prospective for AI productivity gains and how energetically are we embracing those opportunities? Also, to what extent do we allow third party AI agents into our systems, for bookings and the like, and to what extent do we block agents like the way Amazon initially blocked Meta's Muse when it was first launched?
Answer: Was jammed at Dexus so waiting for the archive to see how they responded.
Q4. Australia is currently in the midst of an unprecedented deluge of takeovers that has contributed to listed entities on the ASX dropping by 11% since January 2023 to 2,044 on September 30, 2026. There were a record 27 major takeovers above $100m completed in 2024-25 and this rose to 30 in 2025-26. Why do the chair and CEO believe this is happening? There is a clear mis-pricing between public markets and private markets but is there also a problem with the scrutiny and extra regulation of smaller ASX listed companies, which don't benefit from index investing? Does the chair agree this is a problem for the nation, particularly with so few new floats replenishing the ASX ranks?
Answer: Was jammed at Dexus so waiting for the archive to see how they responded.
Copyright © 2026 The Mayne Report. All rights reserved
